Semaglutide Boca Raton: What the Wegovy Label and Trials Record

The semaglutide Boca Raton patients ask about is usually reduced to one number. The approved labeling carries far more than that: three separate weight trials with different populations, and a cardiovascular outcomes trial in 17,604 people that earned the drug an indication having nothing to do with the scale. This page is built from that record.

Semaglutide Boca Raton: the four things Wegovy is approved for

Most pages about this medicine describe it as a weight loss drug and stop there. The approved labeling is broader, and the extra indications matter because they change who it suits.

The first is cardiovascular: it is indicated “to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight”. The second and third are the weight indications, one covering “adults and pediatric patients aged 12 years and older with obesity” and one covering adults with overweight who also have at least one weight-related condition. The fourth, and newest, is for noncirrhotic MASH with moderate to advanced liver fibrosis.

All of the weight indications are approved for use with a reduced-calorie diet and increased physical activity. That is inside the approved wording, not a footnote to it, and it is why a programme that only hands over a pen is not running the treatment the way it was approved.

Semaglutide carries a boxed warning about the risk of thyroid C-cell tumours, based on findings in rodents, with the relevance to humans not established. It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. That history, and everything else you take, is reviewed before a prescription is considered.

What the three weight trials recorded, and why they differ

The label reports three adult weight trials, all 68 weeks long. They enrolled different people, and that is what separates the results.

Study 2 is the headline trial, and the responder columns are the more useful way to read it: nearly half of treated patients lost at least 15% of their body weight, against fewer than one in twenty on placebo.

Study 3 enrolled people who also had type 2 diabetes, and the mean result is about five points lower. That gap is consistent across this class of medicine. It is not a reason to expect less of the treatment so much as a reason for a programme to know your metabolic picture before it sets a target with you.

The most common side effects are gastrointestinal. The label reports nausea in 44% and diarrhoea in 30% of treated adults, alongside vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia and dizziness among reactions occurring in at least 5% of patients. Most of it concentrates around dose increases, which is the argument for escalating on the schedule rather than ahead of it.

The trial where both groups got real lifestyle support

Study 4 is the one to read if you have ever been told you simply need to try harder.

Every participant in it, on drug or on placebo, received intensive lifestyle intervention for the full 68 weeks. Not a leaflet: structured support. The placebo group, doing that work, lost 5.7%. The treated group, doing the same work, lost 16.0%. More than half of them lost at least 15% of their body weight, against 13.2% of the placebo group.

Two things come out of that. The first is that the lifestyle work is not decoration — it moved the placebo group to nearly 6%, which is more than double what placebo achieved in the trial without it. The second is that it did not close the gap. Both halves of that sentence are worth holding, because a programme built on only one of them either sells you a medication and neglects the rest, or sells you effort and pretends the biology is not there.

It is also the most encouraging number on this page. The best result in the label came from the trial where people got the medicine and the support together, which is the arrangement a programme is for.

The heart result behind the newest indication

The cardiovascular indication rests on the largest trial in this label by a wide margin: 17,604 patients, followed for a median of 41.8 months. It enrolled adults with established cardiovascular disease and either obesity or overweight, and it measured cardiovascular death, non-fatal heart attack and non-fatal stroke.

The result was a statistically significant reduction in those events, with a hazard ratio of 0.80 (95% confidence interval 0.72 to 0.90). That is the basis on which the FDA approved it to reduce cardiovascular risk, and it is the first time a medicine in this category earned an indication of that kind.

Whether it applies to you depends on whether you have established cardiovascular disease, which is a question for your consultation and, where relevant, your cardiologist. It is raised here because it is the part of the record most likely to change the calculation for someone weighing up whether this is worth doing at all.

How the dose is built, and the tablet option

The injection escalates on a fixed schedule, at four-week intervals: 0.25 mg, then 0.5 mg, then 1 mg, then 1.7 mg, then 2.4 mg as the maintenance dose. The early doses are not treatment doses; they exist so that the gastrointestinal effects are manageable by the time you reach the dose the trials studied.

There is now also a tablet, which escalates at thirty-day intervals through 1.5 mg, 4 mg and 9 mg to a 25 mg maintenance dose. The tablet is approved for cardiovascular risk reduction and for weight reduction in adults; it does not carry the pediatric or MASH indications that the injection does. For some people the choice between a weekly injection and a daily tablet is the thing that decides whether a plan survives its first year, so it is worth raising.

Where you settle, and whether either form suits you at all, is a clinical decision made at consultation against your history, your other medications and how you respond. Semaglutide is a prescription medicine. This page exists to tell you what the approved labeling says, so that the appointment starts from the same place you do.

Semaglutide in Boca Raton: how the programme runs at Brazelia MedSpa

The prescription is the easy part. What decides how the year goes is what gets measured, how often you are actually seen, and whether anyone notices when something drifts.

Study 4 is the shape of the programme here, because it is the shape that produced the best result in the label: the medication and the support together, not one standing in for the other. Nutrition, protein intake and resistance training sit inside the plan rather than beside it, and body composition is tracked rather than weight alone, because a reduction of this size takes lean mass with it if nothing is done about that.

Because Brazelia MedSpa runs hormone, metabolic and skin programmes in the same building, the questions that come up along the way have somewhere to go — thyroid and metabolic labs, sleep, the skin laxity that often follows a large reduction, and the plan for holding a result once you reach it.

Semaglutide is one of two medicines used here for this purpose, and the choice between them is not a matter of price. How the two compare, and why the compounded copies still advertised elsewhere no longer rest on the legal basis they once did, is set out on the GLP-1 weight loss page.

New patients start with a consultation. You will hear what the label supports, what it does not, whether this is a sensible fit for you, and what a realistic first year looks like, before anything is scheduled or prescribed.

Frequently asked questions

Sources and how this page was built

Every indication, dose, trial size and percentage on this page was read from the Wegovy (semaglutide) prescribing information on 28 September 2026, and each weight figure is reported with the trial population it came from. Approved indications are quoted in the FDA’s wording. No figure on this page comes from a manufacturer’s marketing material, and no claim is made about outcomes the labeling does not report.

Why patients choose Brazelia MedSpa

This page is the best answer we can give. Most semaglutide pages quote one percentage and a booking button. This one gives you three trials with their populations, the responder rates rather than just the means, and the trial where the placebo group also got real support — because that is the comparison you are actually making in your head, and you deserve to see it settled with data rather than with a slogan.

Weight management at Brazelia MedSpa is run by Khali Reed, CRNA, APRN, in a practice under the medical direction of Dr. Herbert R. Slavin, MD, on site rather than a name on a licence. Prescription weight management is medicine, and it is treated here as medicine rather than as a product.

Brazelia MedSpa has treated patients from the same address in downtown Boca Raton for 18 years, near Mizner Park, and sees patients from across South Florida, from Delray Beach and Boynton Beach to Deerfield Beach and Fort Lauderdale. The programme is run by the same people every visit, which matters more on a medication you take for a year than on a treatment you have once.

Weight is also rarely treated as just weight here. Because Brazelia MedSpa runs hormone, metabolic, skin and regenerative programmes under one roof, thyroid, sleep, training load and the skin changes that follow a large weight reduction can be looked at in the same place, by people who are already talking to each other.

New patients start with a consultation, and nothing is prescribed on a first visit unless it is clinically appropriate and you want to proceed. You will hear what the label supports, what it does not, and what the plan would look like before anything is decided.

This page describes what published labels, regulatory records and peer-reviewed research report about these treatments. It is general health information, not medical advice, and it is not a substitute for a consultation. Whether any treatment is appropriate for you is a clinical judgement that depends on your history and examination.